Steve Purtell Joins ELIQUENT Life Sciences as Chief Financial Officer

ELIQUENT Life Sciences has named Steve Purtell as chief financial officer (CFO). 
 
“Steve’s appointment comes at a pivotal moment for ELIQUENT. As we unify the five Validant Group companies and expand our global footprint, Steve’s leadership and financial expertise will play a critical role in our continued growth,” ELIQUENT Life Sciences CEO Tim Dietlin said.
 
In his role as CFO, Purtell is responsible for directing and executing all of ELIQUENT’s finance activities. This includes partnering with the CEO and executive team to ensure the company’s financial direction aligns with the company’s strategic vision and long-term growth objectives. Purtell will also serve as a key liaison to investors and the financial community while embedding a strong risk and compliance management framework across ELIQUENT’s growing global market.
 
A seasoned finance executive with nearly 30 years’ experience, Purtell has held key roles at multiple public companies across diverse industries. He joined ELIQUENT Life Sciences after more than 10 years at Six Flags, where he served in several finance-related roles, including Interim CFO. As a key advisor to the CEO, Purtell managed external financial relationships, strategic communications, and mergers and acquisitions for the $1.5 billion entertainment company.
 
Purtell also held leadership roles at Siemens Healthcare, where he was vice president of Global Commercial Excellence, vice president of Finance, and treasurer of the company’s $25 billion healthcare division. Before joining Siemens Healthcare, Purtell served in financial roles at Dade Behring, IMC Global, and GATX. Before his corporate career, Purtell was a U.S. Army combat engineer officer and earned a Bronze Star Medal in the Persian Gulf War.
 
Purtell earned a bachelor of science degree in civil engineering from the U. S. Military Academy at West Point and an MBA from the Wharton School.
 
ELIQUENT Life Sciences is the fusion of five global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, and IDEC. The ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
 
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a specialist healthcare investment advisor based in London. The firm applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalization to build businesses of strategic global value. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare.